Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer

OBJECTIVE. To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS. Postme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schwartzberg, Lee S., Franco, Sandra X., Florance, Allison, O'Rourke, Lisa, Maltzman, Julie, Johnston, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2010
Assuntos:
Academia–Pharma Intersect
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227947/
https://ncbi.nlm.nih.gov/pubmed/20156908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0240
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados